BioPharmX Corporation (BPMX)
| Market Cap | 776,821 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 18.28M |
| EPS (ttm) | -0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 18, 2020 |
| Last Price | $0.510 |
| Previous Close | $0.510 |
| Change ($) | 0.000 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 0.456 - 0.525 |
| Day's Volume | 0 |
| 52-Week Range | 0.250 - 1.180 |
News
Biopharmx Corp shares spiked higher Tuesday morning after the company announced its Phase 2b trial of BPX-04 for Populopustular Rosacea has met both primary and secondary endpoints and was wel...
About BPMX
BioPharmX Corporation, a specialty pharmaceutical company, develops products for the treatment of dermatologic conditions using its proprietary HyantX topical delivery system. Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase IIb clinical trials for the treatment of inflammatory lesions of acne; and BPX04, a topical antibiotic, which is in Phase IIb study for the treatment of inflammatory lesions of papulopustular rosacea. The company serves pharmaceutical companies, physician's practices, de... [Read more...]
| Industry Biotechnology | Founded 2014 |
| CEO Steven M. Bosacki | Employees 3 |
| Stock Exchange NYSE American | Ticker Symbol BPMX |